This case highlights the importance of genetic evaluation during treatment in young patients with advanced ovarian cancer. Lynch syndrome caused by a germline MSH6 pathogenic variant was diagnosed during first-line maintenance therapy, and pembrolizumab achieved a durable response in recurrent disease.